Case Studies
Real-world results from our AI-powered antibody engineering platform
3× Increase in Expression Yield
A leading biotech company was struggling with low expression yields for a difficult-to-express therapeutic antibody, with existing platforms delivering only ~1 g/L in fed-batch culture.
Results:
- 3.2 g/L expression yield using our platform
- Stable expression over 50+ generations
- Product quality within specifications
- Project delivered in 12 weeks
Rescued Low-Expression Antibody Project
An IVD company had a critical antibody project that multiple CROs had deemed "impossible to express" at commercially viable yields, threatening their product launch timeline.
Results:
- Successfully expressed the antibody at 2.8 g/L
- Preserved all critical binding properties
- Delivered GMP-grade material in 16 weeks
- Enabled on-time product launch
50% Reduction in Development Timeline
A mid-sized pharmaceutical company needed to accelerate their stable cell line development program to meet clinical trial timelines for their lead antibody candidate.
Results:
- Stable cell line development completed in 10 weeks
- Industry standard timeline is 20-24 weeks
- 2.5 g/L expression yield achieved
- Clinical trial timeline accelerated by 3 months
AI-Designed Antibody with Picomolar Affinity
An academic research group needed high-affinity antibodies against a novel target for their research, with no existing antibodies commercially available.
Results:
- AI-designed antibodies with 50 pM binding affinity
- Highly specific, no cross-reactivity
- Suitable for western blot, IHC, and flow cytometry
- Project completed in 8 weeks
Scaled Production from mg to 100L Scale
A diagnostic company needed to scale up production of their key diagnostic antibody from R&D scale to 100L manufacturing scale while maintaining consistent quality and yield.
Results:
- Consistent yield of 2.7 g/L across all scales
- Product quality identical across scales
- Robust manufacturing process developed
- Continuous supply established for commercial product
Bispecific Antibody Development Success
A biotech startup was developing a novel bispecific antibody for oncology, facing challenges with expression, stability, and manufacturability of the complex molecule.
Results:
- Engineered stable, high-expressing construct
- 1.8 g/L expression yield achieved
- Excellent stability and product quality
- IND-enabling studies now underway